Medicine and Dentistry
Therapeutic Procedure
100%
Aflibercept
100%
Wet Macular Degeneration
100%
Patient
60%
Best Corrected Visual Acuity
40%
Injection
40%
Retinal Pigment Epithelium
40%
Atrophy
40%
Optical Coherence Tomography
40%
Assessment
20%
Adverse Event
20%
Bleeding
20%
Vision
20%
Fluorescein Angiography
20%
Randomized Clinical Trial
20%
Subretinal Fluid
20%
Bevacizumab
20%
Ranibizumab
20%
Thromboembolism
20%
Loading Drug Dose
20%
Nursing and Health Professions
Wet Macular Degeneration
100%
Aflibercept
100%
Injection
40%
Best Corrected Visual Acuity
40%
Atrophy
40%
Optical Coherence Tomography
40%
Central Retinal Thickness
40%
Visual Pigment
40%
Adverse Event
20%
Fluorescence Angiography
20%
Ranibizumab
20%
Bevacizumab
20%
Bleeding
20%
Thromboembolism
20%
Loading Drug Dose
20%
Subretinal Fluid
20%
Pharmacology, Toxicology and Pharmaceutical Science
Aflibercept
100%
Wet Macular Degeneration
100%
Atrophy
40%
Visual Pigment
40%
Adverse Event
20%
Ranibizumab
20%
Bevacizumab
20%
Thromboembolism
20%
Bleeding
20%
Fluorescein
20%
Subretinal Fluid
20%